top of page

Affidea and icometrix, a partnership towards better patient care in Europe

  • Writer: Milan Walraevens
    Milan Walraevens
  • Feb 21, 2019
  • 2 min read

Updated: May 2

LEUVEN, Belgium, and CHICAGO, IL, USA - February 21st, 2019 - Today, Affidea and icometrix announce a strategic partnership, with the goal to further standardize and improve the care of patients with neurological disorders in Europe.


Affidea is the leading European provider of advanced diagnostic imaging services and will implement the icobrain imaging AI portfolio from icometrix. The clinically approved icobrain solutions assist in the enhanced diagnosis and follow-up of people with multiple sclerosis, dementia, and brain trauma. It enables radiologists and neurologists to quantify and track different brain abnormalities on patients’ MRI and CT scans using AI. icobrain presents this information in a concise report, including healthy control data, which aids in the interpretation and communication of the results.


“AI-powered medical imaging systems can help radiologists automate routine procedures and identify subtle changes and patterns,” says Giuseppe Recchi, CEO of Affidea. “icobrain will, therefore, allow physicians to be more efficient and effective in their diagnosis, treatment, and follow-up. It’s an instrument of standardization and precision which will further improve our patient care”, he concludes. Rowland Illing, CMO of Affidea and leading their digital strategy, adds: “Clinical excellence using digital technology is of paramount importance for Affidea. We want to improve patient care by providing the best services to physicians. icobrain will allow us to offer objective and consistent brain imaging measures throughout our network ”


“At icometrix, we are very excited about this collaboration with Affidea,” says Wim Van Hecke, CEO of icometrix. “Combining the expertise and network of Affidea with our icobrain solutions creates many opportunities. Not only will we be able to improve clinical patient care in Europe together, combining our strengths offers a unique setting for real-world studies and clinical trials”.


About Affidea Group

Affidea (www.affidea.com) is the leading European provider of diagnostic imaging, outpatient and cancer care services, operating in 16 countries across Europe, with a focus on delivering timely, thorough diagnostics and high-quality treatments by working only with state-of-the-art technology and experienced medical professionals. The Affidea Group employs over 7500 professionals and operates over 1300 diagnosis and cancer care modalities with almost 13 million diagnostic examinations every year.

bottom of page